Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 June;49(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 June;49(2):205-14

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEW ARTICLES  SINGLE PHOTON EMISSION TOMOGRAPHY


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2005 June;49(2):205-14

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

SPET in psychopharmacolgy

Moresco R. M., Fazio F.

IBFM-CNR, Scientific Institute San Raffaele University of Milan-Bicocca, Milan, Italy


FULL TEXT  


Positron emission tomography (PET) and single photon emission tomography (SPET) permit the in vivo assesment of human biological processes with methods originally developed for preclinical studies. This opportunity is of primary interest in biological psychiatry and in psychoactive drugs development. Most of research efforts have focused on the use of PET field, and several biological finding on central nervous system (CNS) diseases have been published. Despite methodological limitations, the feasibility and usefulness of SPET for research, including full quantification, kinetic modeling and tracer validation, has been clearly demonstrated. The aim of this paper is to review advantages, limitations and results of SPET in psychopharmacology.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail